^
    1d
    NOHA as a key biomarker to link NOS2 activity to immune checkpoint and cytokine signaling in ER-negative breast cancer. (PubMed, Biochem Biophys Rep)
    The pronounced effects in AA-derived ER- spheroids align with known disparities in tumor aggressiveness and suggest future NOHA clinical utility potential in racially diverse populations. Further in vivo validation is warranted to support and confirm such clinical translation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NOS2 (Nitric Oxide Synthase 2)
    |
    ER negative
    5d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354
    5d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    6d
    Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c, lymph node-negative, and hormone receptor-negative breast cancer: a study based on the SEER database and a Chinese cohort (ChiCTR2500115125)
    P=N/A, N=400, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    6d
    Efficacy and Safety of Iparomlimab and Tuvonralimab Combined with Albumin-bound Paclitaxel and Lobaplatin as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer：A Prospective, Multicenter, Single-Arm Study (ChiCTR2500114072)
    P4, N=67, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • lobaplatin (D19466) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6d
    A single-arm, multicenter, phase II clinical trial on sacituzumab tirumotecan with toripalimab in neoadjuvant therapy for triple-negative breast cancer (ChiCTR2600116626)
    P2, N=34, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    6d
    A Phase II, Single-Arm Clinical Study of Goserelin Microspheres for Ovarian Function Preservation During Adjuvant Chemotherapy in Premenopausal Patients with Early Breast Cancer (ChiCTR2500113196)
    P2, N=25, Not yet recruiting, The Third Bethune Hospital of Jilin University; The Third Bethune Hospital of Jilin University
    New P2 trial
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    goserelin acetate
    6d
    Cadonilimab combined with gemcitabine plus carboplatin in metastatic triple-negative breast cancer: a single-arm, multicenter, phase II clinical study (ChiCTR2600117338)
    P2, N=38, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • gemcitabine • Kaitanni (cadonilimab)
    6d
    A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases (ChiCTR2600116792)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule)
    |
    ER negative
    |
    MT027
    6d
    Preoperative Oral Dihydroartemisinin Triple-Negative Breast Cancer: A Single-Center, Open-Label, Single-Arm Pilot Study (ChiCTR2500102437)
    P=N/A, N=8, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Oct 2025
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    9d
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    9d
    Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial (clinicaltrials.gov)
    P2, N=235, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 negative